Sell Cynosure (NSDQ: CYNO) for a 27% gain.
Subscribers of Growth Stock Strategist might still own Cynosure, a stock I recommended last September.
The stock is up 28% today due to a buy out by Hologic for $66 per share in cash. It is unlikely a competing bid will come along so I suggest subscribers sell on this news. Just yesterday fat-busting competitor Zeltiq was purchased by drug heavyweight Allergan for $6 billion. Looks like getting thin is fattening investors’ wallets.
Stock Talk
Robert K
Yes, indeed; still owned it. Thanks Linda!
Linda McDonough
Happy to hear it- congrats!
You must be logged in to post to Stock Talk
You must be logged in to post to Stock Talk
Add New Comments
You must be logged in to post to Stock Talk